医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Vyome Biosciences Announces FDA Acceptance of Investigational New Drug Application in the US for its Lead product VB-1953 to Treat Moderate-to-Severe Acne

2016年01月06日 PM11:00
このエントリーをはてなブックマークに追加


 

NEW DELHI

Vyome Biosciences, a dermatology focused innovative bio-pharmaceutical company, pioneering the development of next generation antibiotics and antifungal products that target antimicrobial resistance for opportunist pathogens of the skin, today announced that the US Food and Drug Administration (US FDA) has accepted its Investigational New Drug (IND) Application for the initiation of clinical studies for its lead program VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon.

According to the American Academy of Dermatology, acne represents the most common skin disease, affecting 85% of teenagers and affects 40-50 million people in the US. Approximately 40% of acne patients are suffering from antibiotic resistance. Physicians around the world have cited a large unmet need for new, improved topical therapy options, vis-à-vis the current available topical products. Vyome’s program VB 1953 targets this large unmet need of an effective topical treatment option.

“Today marks an important milestone for Vyome Biosciences. With the US FDA accepting our first IND application for the lead program VB 1953, we have become a clinical stage company in the USA, which is an important value inflection milestone for us. This should pave the way for further filings with the US FDA in the future. VB 1953 is a first-in-class new product in acne therapy for addressing one of the very important and large unmet needs,” remarked N. Venkat, Co-Founder & CEO at Vyome.

“Successful IND acceptance of VB 1953 by the US FDA, is a culmination of tremendous efforts by Vyome’s product discovery & development team. I am extremely delighted at Vyome’s significant achievement and look forward to more of them in the future,” said Dr. Raghunath Mashelkar, Chairman of Vyome’s Board of Directors.

Apart from the lead program VB 1953, Vyome has a deep R&D pipeline of Dual Action Rational Therapeutics (DARTs) antibiotics that are very less prone to resistance development. Vyome also has a portfolio of clinically tested and commercialized products with superior efficacy for various fungal indications, developed using its breakthrough technology platform Molecular Replacement Therapy (MRTTM).

About Vyome Biosciences Private Limited:

Vyome Biosciences is a clinical-stage, dermatology-based biopharmaceutical company, which has novel platform technologies and a deep pipeline of novel drugs for antibiotic resistant acne, other opportunistic pathogens and antifungal agents. Vyome has put together a team of scientific and management experts from India and USA to deliver the company’s growth plans. Vyome is co-promoted by Shiladitya Sengupta, N. Venkat, Rajesh Gokhale and Rajeev Mantri.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160106005905/en/

CONTACT

Vyome Biosciences
N. Venkat, +91 9848022887
Co-founder & CEO
nvenkat@vyome.in

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Hallstar的新款光稳定剂AvoBrite®在交付卓越防晒产品的同时解决客户面临的监管挑战
  • ホールスターの新しい光安定剤AvoBrite®が、規制に関する課題を解決しつつ、卓越した光防御機能を提供
  • Clinigen Acquires Japan’s Largest Supplier of Unlicensed Medicines
  • Konica Minolta and Innovation Network Corporation of Japan Close Acquisition of Ambry Genetics
  • Median Technologies Appoints Vivian Wang as General Manager, China and Takashi Hayashi as Managing Director, Japan